Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 7Head & Neck 3Gynecologic 3Thoracic 2NET 2Endocrine 2Genitourinary 1

Conditions

Ovarian Neoplasms 535Uterine Cervical Neoplasms 249Fallopian Tube Neoplasms 239Endometrial Neoplasms 142Carcinoma, Ovarian Epithelial 135Breast Neoplasms 101Neoplasms 74Carcinoma, Non-Small-Cell Lung 70Colorectal Neoplasms 53Uterine Cervical Dysplasia 49Papillomavirus Infections 49Neoplasm Metastasis 48Pancreatic Neoplasms 46Melanoma 44Uterine Neoplasms 43Prostatic Neoplasms 41Urinary Bladder Neoplasms 40Lung Neoplasms 40Stomach Neoplasms 38Peritoneal Neoplasms 37Recurrence 36Carcinoma, Renal Cell 35Triple Negative Breast Neoplasms 33Head and Neck Neoplasms 32Esophageal Neoplasms 31Small Cell Lung Carcinoma 30Sarcoma 28Vulvar Neoplasms 26Vaginal Neoplasms 24Testicular Neoplasms 22

Interventions

catumaxomab 1Papanicolaou Test 1Human Papillomavirus DNA Tests 1Colposcopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Neoplasms, Glandular and Epithelial × Gynecologic × Clear all
NCT02164461 2024-05-20

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer

Advaxis, Inc.

Phase 1 Completed
12 enrolled 18 charts
GynecologicThoracic

Adenocarcinoma, Carcinoma, Carcinoma, Squamous Cell, Uterine Cervical Diseases, Uterine Cervical Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Uterine Diseases, Uterine Neoplasms, Carcinoma, Adenosquamous, Carcinoma, Small Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma

NCT01234480 2023-05-16

Intended Use Study of the BD SurePath Plusâ„¢ Pap

Becton, Dickinson and Company

Terminated
5,859 enrolled 4 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Neoplasms, Squamous Cell

NCT00326885 2018-10-17

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Neovii Biotech

Phase 2 Completed
32 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡